

**Shionogi establishes "Medicinal Molecular Imaging Center (Tentative)"
in order to promote joint research with Osaka University
Graduate School of Medicine and Faculty of Medicine**

March 16, 2009 -- Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter "Shionogi") today announced that it has reached a basic agreement on the establishment of "Medicinal Molecular Imaging Center (Tentative)" with Osaka University Graduate School of Medicine and Faculty of Medicine (Dean: Toshio Hirano). The company has been planning to establish the imaging center on the campus of Osaka University in Suita, Osaka, with the school in order to promote their joint research on molecular imaging technologies.

Osaka University Graduate School of Medicine and Faculty of Medicine has been focusing on the development of leading-edge PET/MRI* technology. Shionogi and the school have decided to renovate the north part of the school's radioisotope laboratory and establish "Medicinal Molecular Imaging Center (Tentative)", which has most advanced PET equipments including self-shielding type cyclotron, in order to promote their joint research. Shionogi can use this imaging center through the joint research with the school and promote translational research, which links non-clinical studies to clinical studies, and the company believes that this approach can be applied to strengthen and streamline the pharmaceutical R&D process as well as enhance probability of success. Shionogi also plans to establish a donation course for molecular imaging technology studies in Osaka University Graduate School of Medicine and Faculty of Medicine and the company will work to promote its drug discovery research activities by the study of the donation course and joint research.

Shionogi expects that better medicines can be delivered to patients as soon as possible by the promotion of research exchange in accordance with the philosophy of industrial-academic collaboration by its use of the facility through the study of the donation course and joint research, and by facilitating the bridge between non-clinical and clinical studies.

*PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging): Function/morphology fusion type diagnostic imaging apparatus simultaneously measuring the biofunctional and morphological information.

Overview of the Facility (currently planned):

Name: Medicinal Molecular Imaging Center, Osaka University Graduate School of Medicine and Faculty of Medicine (Tentative)
Building: Building area of approximately 500m², part of the radioisotope laboratory, three stories
Address: Osaka University Suita Campus, 2-2, Yamadaoka, Suita, Osaka 565-0871
Total Construction Cost: Approximately 400 million yen
Construction Schedule: Begin construction in March 2009 and completed in April 2010
Design and Construction: Sumitomo Heavy Industries, Ltd.

Shionogi and Osaka University Graduate School of Medicine and Faculty of Medicine plan to discover their joint research theme by "FLASH (PHarma-Link between Academia and SHionogi)", which is an event inviting research theme from researchers in both organizations in order to widely bridge their collaborative relationship with drug discovery. FLASH is not only just a research promotion system but also the event playing a variety of roles in the exchange of their young researchers and human resource development. It will be a model case seeking a new style of industrial-academic collaboration. Shionogi expects the event to create fledgling joint researches, which grow up to the future drug seeds and link to the generation of new drugs saving people suffering from ill health around the world.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to

update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information:

Shionogi & Co., Ltd., Corporate Communications Department

Tel: +81-6-6209-7885 Fax: +81-6-6229-9596